The federal body's appeal to COVID vaccine makers comes at a time when the United States is moving to a commercial marketplace for COVID products from government purchases in the early years of the pandemic. In a letter to vaccine manufacturers Pfizer/BioNTech, Moderna and Novavax, HHS said it expects them to prepare for an ample supply for the 2023-24 fall vaccination campaign, and remain prepared to support any potential surges in demand and evolving COVID-19 situations. While Moderna and Pfizer have not settled on a price, the companies are planning to target a range of commercial price of $110 to $130 a dose for their vaccines.
Туристы тратят за одну покупку в Петербурге почти 1,5 тыс. рублей dp.ru - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dp.ru Daily Mail and Mail on Sunday newspapers.